| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4db5cbe5fd23c366c54c0b69c8766a7c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5154
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-124
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-1114
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-1157
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0634
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0693
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-805
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0641
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0645 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0786
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2015-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41e0e166afd9a6b6f84d09bbfee8055b |
| publicationDate |
2016-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2016058793-A1 |
| titleOfInvention |
Tumor Targeted Sickle Erythroid Precursors, Progenitors and Hematopoietic Stem Cells, Induced Pluripotent Stem Cells, Microparticles and Liposomes for Treatment of Cancer |
| abstract |
The present invention contemplates a method of treating cancer comprising CD47 deficient sickle cell erythroid precursors/progenitors or hematopoietic stem cells transduced with viral altered genomic DNA from normal or tumor bearing hosts and used to polarize macrophages and/or activate a cytotoxic T cell tumoricidal response. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11766454-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10780117-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018344642-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11116726-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019133881-A1 |
| priorityDate |
1999-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |